PDGFRA and gastrointestinal stromal tumor: Avapritinib (formerly BLU-285, Blueprint Medicines Corporation, Cambridge, Massachusetts, USA) is a selective, potent inhibitor of KIT and PDGFRA mutant kinases, which is currently approved in the US for the treatment of adults with unresectable or metastatic GIST that harbor a PDGFRA exon 18 mutation, including D842V [18].